Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557)
Authors:
- Hans Otto KleinHKHans Otto Klein
- Premaratne Dias WickramanayakePWPremaratne Dias Wickramanayake
- Edith ChristianECEdith Christian
- Claudia CoerperCCClaudia Coerper
Abstract
This report describes some experimental and clinical studies showing the following: (1) in animals under protection of mesna the dose of ifosfamide (Ifo) can be increased significantly; (2) fractionated administration of Ifo, cyclophosphamide (CPA), or the stabilized metabolite of cyclophosphamide (ASTA Z 7557) is less toxic than single push-injection of the same total daily dose and therapeutically more effective; and (3) in humans under the protection of mesna the continuous infusions of ifosfamide over 5 days leads to an increase of the MTD compared with single daily short-term infusion and responses in some solid tumors, e.g., soft tissue sarcomas.Keywords
This publication has 7 references indexed in Scilit:
- Therapeutic effects of single-push or fractionated injections of cyclophosphamide or ifosfamide combined with mesnaCancer Treatment Reviews, 1983
- High-dose ifosfamide and mesna as continuous infusion over five days—a phase I/II trialCancer Treatment Reviews, 1983
- High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcomaCancer Treatment Reviews, 1983
- Oxazaphosphorine Cytostatics: Structure—Activity Relationships, Selectivity and Metabolism, Regional Detoxification1983
- Fluorometrische Bestimmung von ?aktiviertem? Cyclophosphamid und Ifosfamid im BlutJournal of Cancer Research and Clinical Oncology, 1979
- Quantitative Untersuchungen zum Wachstumsverhalten eines diploiden Ehrlich- und des MCa1-Ascitestumors der MausJournal of Cancer Research and Clinical Oncology, 1968
- Tissue sulfhydryl groupsArchives of Biochemistry and Biophysics, 1959